上传结核病资料.ppt

结核病防治的面临的临床挑战与诊治进展;Tuberculosis: Back on the Immunologists’ Agenda. Immunity 24, 351–357, April 2006;Tuberculosis: Back on the Immunologists’ Agenda. Immunity 24, 351–357, April 2006;化疗前时代;新发病例中的耐药结核比例WHO ;Resistance in Previously treated USA Rus Gem Henan Zhej ShanD Hongkong INH 15.4% 42.7% 16.0 48.8% 44.3% 40.5% 17.4% RFP 8.0% 31.0% 6.6% 43.5% 45.0% 23.2% 11.6% EMB 4.1% 21.1% 3.9% 18.9% 17.9% 10.5% 6.0% SM 8.3% 53.4% 7.0% 50.7% 27.9% 34.5% 16.3% MDR 5.6% 26.7% 6.3% 34.4% 35.0% 19.5% 9.6%;泛耐药(XDR)结核已经出现 ;XDR ;结核病的标准治疗与耐药的治疗问题;以DOTS为基础的个体化治疗;耐药基因用于耐药性检测;MDR 与药物开发;抗结核药物分组;如何避免继发性耐药;影响中国结核发病率的关键因素;结核菌的快速培养系统; BD BACTEC 460 TB 的升级产品----BACTEC? MGIT 960 全自动分枝杆菌??测系统;;皮肤试验;检测γ-干扰素分泌的酶联斑点试验;卡介苗的进化过程与结核菌素皮试的交叉反应;原理;胸片;肺ＣＴ;会诊;治疗前后对照;Elispot结果;治疗前后;结核控制与潜伏感染; New TB cases are driven by the reservoir of latently infected people. If we want to stop active TB cases, we need to eliminate this reservoir of infection. This “hidden epidemic” of people infected with latent TB is enormous. The growth in latent TB is becoming a clinical time bomb. We need to defuse this bomb by increasing our efforts to identify and treat latently infected people. ;2015年前全球结核控制策略;Thank you